Xvivo Perfusion AB (publ)
XVIPY · OTC
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $15 | $9 | $6 | $4 |
| - Cash | $0 | $1 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | $15 | $8 | $5 | $4 |
| Revenue | $1 | $1 | $0 | $0 |
| % Growth | 37.6% | 43.9% | 60.7% | – |
| Gross Profit | $1 | $0 | $0 | $0 |
| % Margin | 75% | 74.5% | 71.5% | 72.9% |
| EBITDA | $0 | $0 | $0 | $0 |
| % Margin | 13.5% | 28.8% | 9.4% | 15.2% |
| Net Income | $0 | $0 | $0 | $0 |
| % Margin | 20.9% | 15.4% | 4.4% | 3.2% |
| EPS Diluted | 1.36 | 0.77 | 0.16 | 0.07 |
| % Growth | 76.6% | 381.3% | 128.6% | – |
| Operating Cash Flow | $0 | $0 | $0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | $0 | -$0 | -$0 | -$0 |